63. 特発性血小板減少性紫斑病 Idiopathic thrombocytopenic purpura Clinical trials / Disease details


臨床試験数 : 363 薬物数 : 212 - (DrugBank : 43) / 標的遺伝子数 : 47 - 標的パスウェイ数 : 138

  
20 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR2000035408
2020-08-202020-08-10A randomized controlled study for rituximab in first-line treatment of newly diagnosed immune thrombocytopeniaStudy of rituximab in first-line treatment of newly diagnosed immune thrombocytopenia Idiopathic Thrombocytopenic PurpuraStandard dose group:Rituximab (Hanrikang) 375mg/m2, 4 times a week (day 8, 15, 22, 29).;Low-dose group:Rituximab (Hanrikang) 100mg/ time once a week, administered 4 times (day 8, 15, 22 and 29).;Dexamethasone control group:high-dose dexamethasone (HD-DXM), 40mg/d, iv for 4 days (day 1 to day 4), every 15 days, 2 to 4 cycles, until CR or the end of the study.;Henan Cancer HospitalNULLRecruiting1865BothStandard dose group:20;Low-dose group:20;Dexamethasone control group:20;Phase 4China
2NCT04518475
(ClinicalTrials.gov)
August 10, 202012/8/2020Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in AdultsA Multicenter, Randomized, Open-label Study To Compare The Efficacy And Safety Of Eltrombopag Combining Rituximab With Eltrombopag In Adult ITP PatientsPrimary Immune Thrombocytopenia (ITP)Drug: eltrombopag combining rituximab;Drug: eltrombopagInstitute of Hematology & Blood Diseases HospitalThe Second Affiliated Hospital of Kunming Medical University;Henan Cancer Hospital;Tianjin Medical University Second Hospital;The First Affiliated Hospital of Xiamen University;Nantong UniversityRecruiting18 Years60 YearsAll224Phase 4China
3ChiCTR2000030603
2020-05-012020-03-08Clinical study on the safety and efficacy of short - course glucocorticoid treatment in patients with refractory glucocorticoid-dependent primary immune thrombocytopeniaClinical study on the safety and efficacy of short - course glucocorticoid treatment in patients with refractory glucocorticoid-dependent primary immune thrombocytopenia Primary Immune ThrombocytopeniaThe short -course glucocorticoid group:treat with glucocorticoid;The eltrombopag group:treat with eltrombopag;The rituximab group:treat with rituximab;Splenectomy group:treat with splenectomy;The azathioprine group:treat with azathioprine;The cyclosporine group:treat with cyclosporine;The Second Affiliated Hospital of Kunming Medical UniversityNULLPending1875BothThe short -course glucocorticoid group:65;The eltrombopag group:65;The rituximab group:65;Splenectomy group:65;The azathioprine group:65;The cyclosporine group:65;Phase 4China
4ChiCTR1900027748
2019-12-012019-11-25Clinical study of rituximab in the treatment of refractory immune thrombocytopeniaClinical study of rituximab in the treatment of refractory immune thrombocytopenia Primary Immune ThrombocytopeniaCase series:Treating with rituximab (hanlikan);Department of Hematology, the Second Affiliated Hospital of Kunming Medical UniversityNULLPendingBothCase series:60;Phase 4China
5NCT03443570
(ClinicalTrials.gov)
March 1, 201818/2/2018Rituximab Combining Bortezomib Versus Rituximab in Management of ITPA Multicenter Prospective Randomized Study of Rituximab Combined With Bortezomib Versus Rituximab in the Treatment of Newly Diagnosed Primary Immune Thrombocytopenia (ITP)Immune Thrombocytopenia;Purpura, Thrombocytopenic, IdiopathicDrug: Rituximab;Drug: BortezomibShandong UniversityThe Affiliated Hospital of Qingdao University;Yantai Yuhuangding HospitalNot yet recruiting18 Years75 YearsAll200Phase 3China
6EUCTR2015-005276-14-DK
(EUCTR)
08/12/201619/10/2016Maintenance treatment With rituximab in ITPProlonging the response by low-dose Rituximab maintenance therapy in immune thrombocytopenia: a randomized placebo-controlled trial- the PROLONG trial. - PROLONG-trial Immune thrombocytopenia
MedDRA version: 23.0;Level: LLT;Classification code 10021245;Term: Idiopathic thrombocytopenic purpura;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
Trade Name: Mabthera
Product Name: rituximab
Trade Name: Dexamethasone Abcur
Product Name: Dexamethasone
Sykehuset Østfold HFNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
130Phase 3France;Egypt;Denmark;Norway;Tunisia
7NCT01734057
(ClinicalTrials.gov)
July 201221/11/2012Recombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)A Multicentre Investigation of Recombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)Purpura;Idiopathic Thrombocytopenic PurpuraDrug: recombinant human thrombopoietin (rhTPO); rituximab;Drug: DexamethasoneShandong UniversityThe Affiliated Hospital of the Chinese Academy of Military Medical Sciences;Anhui Medical University;The First Affiliated Hospital of Dalian Medical University;Shandong Provincial Hospital;Shenzhen Second People's Hospital;China Medical University, China;Zhejiang Provincial Hospital of TCMWithdrawn18 Years75 YearsBoth0Phase 3China
8JPRN-JMA-IIA00070
31/10/201112/08/2011R-ITP: Clinical Evaluation of Rituximab in Primary Immune ThrombocytopeniaR-ITP: Clinical Evaluation of Rituximab in Primary Immune Thrombocytopenia Idiopathic Thrombocytopenic PurpuraIntervention type:DRUG. Intervention1:rituximab, Dose form:INJECTION, Route of administration:INTRAVENOUS DRIP.Keio University School of Medicine , Yoshitaka miyakawaNULLCompleted>=20 YEARSNo LimitBOTH24Phase 3Japan
9NCT01525836
(ClinicalTrials.gov)
May 201131/1/2012rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITPRecombinant Human Thrombopoietin in Combination With Rituximab Versus Low-dose Rituximab for the Treatment of Refractory ITP.Purpura;Idiopathic Thrombocytopenic PurpuraDrug: rituximab; recombinant human thrombopoietin (rhTPO);Drug: RituximabShandong UniversityThe Affiliated Hospital of the Chinese Academy of Military Medical Sciences;The First Affiliated Hospital of Anhui Medical University;The First Affiliated Hospital of Dalian Medical University;Shandong Provincial Hospital;Shenzhen Second People's Hospital;First Hospital of China Medical UniversityCompleted18 Years72 YearsBoth123Phase 3China
10NCT03258866
(ClinicalTrials.gov)
January 1, 201018/8/2017The Study of Different Dose Rituximab in the Treatment of ITPThe Clinical Randomized Controlled Study of Different Dose Rituximab in the Treatment of Primary Immune ThrombocytopeniaPurpura, Thrombocytopenic, Idiopathic;Immune ThrombocytopeniaDrug: RituximabShandong UniversityNULLCompleted10 Years70 YearsAll62Phase 4China
11NCT01506414
(ClinicalTrials.gov)
June 200916/11/2011Recombinant Human Thrombopoietin in Combination With Rituximab in Immune Thrombocytopenia (ITP)A Multicentre Investigation of Recombinant Human Thrombopoietin (Rh-TPO) Combine With Low-dose Rituximab in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia (ITP)Purpura;Idiopathic Thrombocytopenic PurpuraDrug: rhTPO in combination with RituximabMing HouPeking Union Medical College Hospital;Chinese Academy of Medical Sciences;First Affiliated Hospital, Sun Yat-Sen University;West China Hospital;Shandong Provincial Hospital;Wuhan Union Hospital, China;Zhejiang UniversityCompleted16 Years75 YearsBoth91Phase 3China
12EUCTR2005-005918-20-FR
(EUCTR)
23/12/200823/10/2008Rituximab as second line treatment for ITP:A Multicentre, Randomized, Double blind, Placebo-controlled, Phase III study.The RITP study” - RITP studyRituximab as second line treatment for ITP:A Multicentre, Randomized, Double blind, Placebo-controlled, Phase III study.The RITP study” - RITP study Immune thrombocytopenic purpura (ITP)
MedDRA version: 9.1;Level: LLT;Classification code 10021245;Term: Idiopathic thrombocytopenic purpura
Trade Name: MabThera
Product Name: MabThera
Other descriptive name: RITUXIMAB
RikshospitaletNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
110Phase 3United Kingdom;France;Sweden
13NCT00749112
(ClinicalTrials.gov)
August 20088/9/2008Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune CytopeniasLow Doses of Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune CytopeniasIdiopathic Thrombocytopenic Purpura;Anemia, Hemolytic, AutoimmuneDrug: Alemtuzumab, RituximabHospital Universitario Dr. Jose E. GonzalezNULLCompleted16 YearsN/ABoth19Phase 2/Phase 3Mexico
14NCT00475423
(ClinicalTrials.gov)
May 200717/5/2007A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.An Open Label Study of a Fixed Dose Regimen of MabThera on Overall Response Rate in Patients With Refractory, Relapsing or Chronic Idiopathic Thrombocytopenic Purpura.Idiopathic Thrombocytopenic PurpuraDrug: rituximab [MabThera/Rituxan]Hoffmann-La RocheNULLCompleted18 YearsN/AAll122Phase 2Australia
15NCT00770562
(ClinicalTrials.gov)
July 20059/10/2008A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)A Randomized, Open-label Study of First-line Treatment With Dexamethasone or Dexamethasone Plus MabThera on Sustained Treatment Response in Adult Patients With Idiopathic Thrombocytopenic PurpuraIdiopathic Thrombocytopenic PurpuraDrug: rituximab;Drug: DexamethasoneHoffmann-La RocheNULLCompleted18 YearsN/AAll103Phase 3Italy
16EUCTR2005-000859-15-IT
(EUCTR)
14/04/200520/06/2005Randomized prospective study comparing dexamethasone and dexamethasone plus rituximab in the treatment of idiopathic thrombocytopenic purpura (ITP) in adults.Randomized prospective study comparing dexamethasone and dexamethasone plus rituximab in the treatment of idiopathic thrombocytopenic purpura (ITP) in adults. Front-line treatment of adult ITP
MedDRA version: 6.1;Level: PT;Classification code 10021245
Trade Name: Mabthera
INN or Proposed INN: Rituximab
Trade Name: Mabthera
INN or Proposed INN: Rituximab
ROCHENULLNot RecruitingFemale: yes
Male: yes
Italy
17NCT01713855
(ClinicalTrials.gov)
October 200418/10/2012Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic PurpuraVaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura (ITP)Idiopathic Thrombocytopenic Purpura;Immune Thrombocytopenic PurpuraBiological: Inactivated Trivalent Influenza vaccineNeufeld, Ellis J, MD, PhDTerrana ITP Research FundCompleted18 Months18 YearsBoth10N/AUnited States
18NCT00909077
(ClinicalTrials.gov)
August 200426/5/2009The Efficacy of Dexamethasone Versus Dexamethasone Combined With Rituximab in Patients With Newly Diagnosed Idiopathic Thrombocytopenic Purpura (ITP)A Randomised Phase III Study of the Efficacy of High Dose Dexamethasone Versus High Dose Dexamethasone in Combination With Rituximab (MabThera®)in Patients With Newly Diagnosed Idiopathic Thrombocytopenic Purpura (ITP)Idiopathic Thrombocytopenic PurpuraDrug: Dexamethasone;Drug: Dexamethasone and RituximabCopenhagen University Hospital at HerlevNULLCompleted18 YearsN/AAll155Phase 3Denmark
19NCT00161564
(ClinicalTrials.gov)
February 20048/9/2005A Trial to Treat Patients With ITP Who Do Not Achieve a Durable Response to Rituxan AloneA Randomized Trial Comparing Higher Doses of Rituximab (Rituxan) With Standard Doses of Rituxan in Combination With CVP (Cyclophosphamide, Vincristine,and Prednisone) in Subjects With Chronic ITP Who Have Failed/Relapsed After Rituxan TreatmentIdiopathic Thrombocytopenic Purpura (ITP)Drug: RituximabWeill Medical College of Cornell UniversityGenentech, Inc.Withdrawn12 YearsN/AAll0Phase 2United States
20NCT01713738
(ClinicalTrials.gov)
May 200318/10/2012Clinical Trial of Rituximab in Children and Adolescents With Chronic Idiopathic Thrombocytopenic Purpura (ITP)Open Label, Phase I/II Trial of Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura (ITP)in Children and AdolescentsIdiopathic Thrombocytopenic Purpura (ITP);Immune Thrombocytopenic Purpura (ITP)Drug: rituximabNeufeld, Ellis J, MD, PhDGenentech, Inc.;Biogen Idec;Glaser Pediatric Research Network;Terrana ITP Research FundCompleted18 Months18 YearsBoth36Phase 1/Phase 2United States